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Background
What is Photodynamic Therapy?
 Photodynamic Therapy 
(PDT): treating cancer 





The structure of a porphyrin molecule. 
Chemical formula C20H14N4
 Known for their role in hemoglobin
 Alternating single and double bonds 
give aromaticity and stabilization
 Create singlet, molecular oxygen, 
resulting in cytotoxicity of the tumor 
tissue cells
How is PDT Currently 
Being Used?
Three Photosensitizers
Photofrin® Foscan® 5-Aminolevulinic Acid
Photofrin®
 Most studied photosensitive agent
 Reliable and easily activated
 Prolonged skin sensitivity
Foscan®
 Great tumor selectivity and deeper light 
penetration
 Only approved in Europe
5-Aminolevulinic 
Acid
 Only for superficial lesions
 Clears from body in 48 hours




Formation of the Acid-
Chloride Porphyrin
Formation of the Final Product, 
H2TPP-Pro-OH
Purification
















Top: UV-Vis results for H2TPP-
Pro-OH.
Bottom: Peaks (nm) and 
epsilon (ε) values for the UV-vis 
spectroscopy of H2TPP-Pro-
OH. Epsilon values calculated 
using Beer’s Law: A= 𝜀𝜀c𝑙𝑙.
1H Nuclear Magnetic Resonance 
Spectroscopy
Results from 1H NMR spectroscopy of the 
free amine, 
(S)-(+)-prolinol, in CDCl3.
Results from 1H NMR spectroscopy of final 
product, 
H2TPP-Pro-OH, in D2O.
High Performance Liquid Chromatography
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Testing
MTT Assay Procedure
 Method of measuring 
cellular metabolic 
activity and determining 
cell viability
 MTT assay results after 72 
hours of incubation. The 
left plate was entirely in 
dark conditions, while 
the right plate was 
exposed to light. The 
purple color indicates 
living cells.
MTT Assay Results
 Spectrophotometric MTT assay results for 
trial one of the light and dark 96-well plates. 
The porphyrin concentrations used were 1, 
3, 10, 30, and 100 µM 
 Spectrophotometric MTT assay results for 
trial two of the light and dark 96-well plates. 
The porphyrin concentrations used were 30, 
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